MODERNA AND MERCK SAY THEIR MRNA CANCER VACCINE CUT DEATH, RECURRENCE BY 42%

Summary from the TLDR newsletter

Moderna and Merck's personalized mRNA vaccines against melanoma demonstrate how mRNA technology has the potential to fundamentally challenge how cancer is treated. The vaccine's success offers a new paradigm for cancer therapies. The companies are already engaging with regulatory authorities to get the vaccine approved.